Drug intelligence / Profile preview

NKL-012

Development stage: Preclinical
Lead developer: NKILT Therapeutics

Overview

NKL-012 is a drug candidate developed by NKILT Therapeutics, Inc. It functions as a modulator of HLA-G (major histocompatibility complex, class I, G), a protein known to play a role in immune regulation. The drug is currently in the discovery phase of development and is being investigated for its potential therapeutic applications in neoplasms and hemic and lymphatic diseases, with a specific focus on hematologic neoplasms.

Targets

HLA-G (Human leukocyte antigen G)

Beyond the preview

Go deeper on NKL-012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKL-012.

Explore the full profile